H.C. Wainwright Thinks Oragenics Inc’s Stock is Going to Recover

By Austin Angelo

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oragenics Inc (OGENResearch Report) today and set a price target of $2. The company’s shares closed yesterday at $0.55, close to its 52-week low of $0.38.

Selvaraju observed:

“We believe the Phase 2 study could report top-line results in early 2020. If AG013 could significantly reduce the duration and lower the incidence of 2 data may serve as one of the two pivotal data sets required to support regulatory filing, in our view. AG013 has been granted Fast Track designation in the U.S. and Orphan Drug status in Europe. In the wake of this update, we reiterate our Buy rating and $2 price target. Preclinical data of lantibiotics published. Lantibiotics have been developed to possess both strong antimicrobial properties as well as the ability to evade common resistance mechanisms. Last week, preclinical data of the company’s lantibiotic compound, OG253, were published in Toxicology and Applied Pharmacology.”

According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -1.8% and a 31.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Oragenics Inc is a Moderate Buy with an average price target of $2.

See today’s analyst top recommended stocks >>

Based on Oragenics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $2.76 million. In comparison, last year the company had a GAAP net loss of $2.12 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of lantibiotics and genetically engineered bacterial strains.